Dongkook Pharmaceutical at AAPS 2026 PharmSci 360
Oct 25–28, 2026 New Orleans, LA ~4k attendees Website
Dongkook Pharmaceutical brings 2 presentations to AAPS 2026 PharmSci 360 in New Orleans. Dongkook Pharmaceutical's program centres on complex injectables that must match a reference medicine. Its work covers a long-acting leuprolide microsphere depot shown to be bioequivalent and reproducible at commercial scale, and a liposomal amphotericin B with established equivalence.
| Organization | AAPS 2026 PharmSci 360 Attendance |
|---|---|
Dongkook Pharmaceutical Seoul, South Korea | |
South Korean pharmaceutical company making prescription medicines, consumer health products and cosmetics. | Poster Tue Oct 27 11:30am–12:30pm Long-Acting Injectable Leuprolide Acetate Microsphere Depot: Establishment of Bioequivalence and Commercial-Scale Reproducibility Poster Tue Oct 27 3:30pm–4:30pm Development of Liposomal Amphotericin B with Established Pharmaceutical Equivalence and Clinical Bioequivalence |
Instantly find 20 buyers from Dongkook Pharmaceutical
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Association of Pharmaceutical Scientists (AAPS). Submit a correction